Is CLDX or ZBIO more profitable?

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -50.72% -46.59% Zenas BioPharma N/A -99.99% -58.06%

Does the media favor CLDX or ZBIO?

In the previous week, Zenas BioPharma had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Zenas BioPharma's score of 0.64 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NVAX or ZBIO?

In the previous week, Novavax had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Novavax's score of 0.24 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, INVA or ZBIO?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.98 $271.17M $6.01 3.69 Zenas BioPharma $10M 116.03 -$377.74M -$8.47 N/A

Does the media prefer INVA or ZBIO?

In the previous week, Innoviva had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Innoviva and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Innoviva's score of 0.09 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MNKD or ZBIO?

In the previous week, MannKind had 12 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for MannKind and 3 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.81 beat Zenas BioPharma's score of 0.64 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zenas BioPharma (ZBIO) Competitors

$18.38 +0.98 (+5.63%)

Closing price 04:00 PM Eastern

Extended Trading

$18.39 +0.01 (+0.05%)

As of 04:10 PM Eastern

Compare

ZBIO vs. CLDX, BCRX, NVAX, INVA, and MNKD

Should you buy Zenas BioPharma stock or one of its competitors? MarketBeat compares Zenas BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zenas BioPharma include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market.

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Zenas BioPharma	N/A	-99.99%	-58.06%

Celldex Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,525.46	-$258.76M	-$4.26	N/A
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

Celldex Therapeutics currently has a consensus price target of $49.78, indicating a potential upside of 66.31%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 140.95%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zenas BioPharma had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Zenas BioPharma's score of 0.64 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Zenas BioPharma on 10 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its stock price is 171% less volatile than the broader market.

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, indicating a potential upside of 143.73%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 140.95%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Zenas BioPharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, Zenas BioPharma had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 3 mentions for Zenas BioPharma and 0 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.82 beat Zenas BioPharma's score of 0.64 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Very Positive
Zenas BioPharma	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$885.72M	2.44	$263.86M	-$1.78	N/A
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Novavax?

Novavax (NASDAQ:NVAX) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Novavax presently has a consensus target price of $12.13, indicating a potential upside of 18.99%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 140.95%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Novavax had 5 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Novavax and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Novavax's score of 0.24 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market.

Novavax has higher revenue and earnings than Zenas BioPharma. Novavax is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.49	$440.30M	-$0.58	N/A
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

Zenas BioPharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

Novavax and Zenas BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.98	$271.17M	$6.01	3.69
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

In the previous week, Innoviva had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for Innoviva and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.64 beat Innoviva's score of 0.09 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-99.99%	-58.06%

Innoviva presently has a consensus target price of $36.20, indicating a potential upside of 63.36%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 140.95%. Given Zenas BioPharma's higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, meaning that its share price is 171% less volatile than the broader market.

Summary

Innoviva beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to MannKind?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

MannKind has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its stock price is 171% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-99.99%	-58.06%

49.5% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$360.78M	3.01	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	116.03	-$377.74M	-$8.47	N/A

MannKind currently has a consensus target price of $8.97, suggesting a potential upside of 154.79%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 140.95%. Given MannKind's stronger consensus rating and higher possible upside, research analysts plainly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, MannKind had 12 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for MannKind and 3 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.81 beat Zenas BioPharma's score of 0.64 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Zenas BioPharma on 12 of the 16 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.16B	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-2.17	18.72	23.87	24.40
Price / Sales	116.03	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	4.08	6.80	9.99	6.73
Net Income	-$377.74M	$24.09M	$3.56B	$337.03M
7 Day Performance	-0.97%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	92.46%	48.95%	28.77%	34.24%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	3.6835 of 5 stars	$18.38 +5.6%	$44.29 +140.9%	+82.8%	$1.16B	$10M	N/A	N/A	Analyst Forecast
CLDX Celldex Therapeutics	2.6382 of 5 stars	$28.90 -4.1%	$49.78 +72.2%	+49.7%	$2.37B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.4167 of 5 stars	$8.34 -2.7%	$20.70 +148.2%	-26.3%	$2.18B	$874.84M	N/A	530	Positive News Analyst Forecast
NVAX Novavax	2.0344 of 5 stars	$10.21 -2.9%	$12.13 +18.8%	+40.5%	$1.73B	$596.34M	N/A	1,990
INVA Innoviva	3.3468 of 5 stars	$21.35 -0.7%	$36.20 +69.6%	+5.3%	$1.59B	$411.33M	3.55	100	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. CLDX, BCRX, NVAX, INVA, and MNKD

How does Zenas BioPharma compare to Celldex Therapeutics?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Novavax?

Summary

How does Zenas BioPharma compare to Innoviva?

Summary

How does Zenas BioPharma compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. CLDX, BCRX, NVAX, INVA, and MNKD

How does Zenas BioPharma compare to Celldex Therapeutics?

Which has more risk & volatility, CLDX or ZBIO?

Is CLDX or ZBIO more profitable?

Which has higher earnings and valuation, CLDX or ZBIO?

Do analysts rate CLDX or ZBIO?

Does the media favor CLDX or ZBIO?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Do institutionals & insiders hold more shares of BCRX or ZBIO?

Which has more risk & volatility, BCRX or ZBIO?

Do analysts rate BCRX or ZBIO?

Is BCRX or ZBIO more profitable?

Does the media favor BCRX or ZBIO?

Which has higher earnings and valuation, BCRX or ZBIO?

Summary

How does Zenas BioPharma compare to Novavax?

Do analysts recommend NVAX or ZBIO?

Do institutionals and insiders have more ownership in NVAX or ZBIO?

Does the media favor NVAX or ZBIO?

Which has more volatility & risk, NVAX or ZBIO?

Which has preferable earnings and valuation, NVAX or ZBIO?

Is NVAX or ZBIO more profitable?

Summary

How does Zenas BioPharma compare to Innoviva?

Which has better valuation & earnings, INVA or ZBIO?

Does the media prefer INVA or ZBIO?

Is INVA or ZBIO more profitable?

Do analysts prefer INVA or ZBIO?

Do institutionals & insiders believe in INVA or ZBIO?

Which has more volatility & risk, INVA or ZBIO?

Summary

How does Zenas BioPharma compare to MannKind?

Which has more risk & volatility, MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Do insiders & institutionals have more ownership in MNKD or ZBIO?

Which has stronger valuation & earnings, MNKD or ZBIO?

Do analysts recommend MNKD or ZBIO?

Does the media prefer MNKD or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools